<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title>BMC Genomics</journal-title><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-9-606</article-id><article-id pub-id-type="pmid">19087315</article-id><article-id pub-id-type="doi">10.1186/1471-2164-9-606</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Differential RelA- and RelB-dependent gene transcription in LT&#x003b2;R-stimulated mouse embryonic fibroblasts</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Lovas</surname><given-names>Agnes</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lovas@fli-leibniz.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Radke</surname><given-names>D&#x000f6;rte</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>doerte.radke@uni-greifswald.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Albrecht</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>daniela.albrecht@hki-jena.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Yilmaz</surname><given-names>Z Buket</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>yilmaz@mdc-berlin.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>M&#x000f6;ller</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ulrich.moeller@hki-jena.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Habenicht</surname><given-names>Andreas JR</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>andreas.habenicht@mti.uni-jena.de</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Weih</surname><given-names>Falk</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fweih@fli-leibniz.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Research Group Immunology, Leibniz Institute for Age Research, Fritz Lipmann Institute, Beutenbergstrasse 11, 07745 Jena, Germany</aff><aff id="I2"><label>2</label>Bioinformatics &#x02013; Pattern Recognition, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Kn&#x000f6;ll-Institute, Beutenbergstrasse 11a, 07745 Jena, Germany</aff><aff id="I3"><label>3</label>Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Kn&#x000f6;ll-Institute, Beutenbergstrasse 11a, 07745 Jena, Germany</aff><aff id="I4"><label>4</label>Signal Transduction in Tumor Cells, Max Delbr&#x000fc;ck Center for Molecular Medicine, Robert R&#x000f6;ssle Strasse 10, 13092 Berlin-Buch, Germany</aff><aff id="I5"><label>5</label>Institute for Vascular Medicine, Friedrich Schiller University of Jena, Bachstrasse 18, 07743 Jena, Germany</aff><aff id="I6"><label>6</label>Institute for Community Medicine, Ernst Moritz Arndt University Greifswald, Walther Rathenau Strasse 48, 17475 Greifswald, Germany</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2008</year></pub-date><volume>9</volume><fpage>606</fpage><lpage>606</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/9/606"/><history><date date-type="received"><day>3</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Lovas et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Lovas et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Lovas Agnes lovas@fli-leibniz.de </dc:author><dc:title> Differential RelA- and RelB-dependent gene transcription in LT&#x003b2;R-stimulated mouse embryonic fibroblasts </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Genomics 9(1): 606-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2008)9:1&#x0003c;606&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Lymphotoxin signaling via the lymphotoxin-&#x003b2; receptor (LT&#x003b2;R) has been implicated in biological processes ranging from development of secondary lymphoid organs, maintenance of spleen architecture, host defense against pathogens, autoimmunity, and lipid homeostasis. The major transcription factor that is activated by LT&#x003b2;R crosslinking is NF-&#x003ba;B. Two signaling pathways have been described, the classical inhibitor of NF-&#x003ba;B &#x003b1; (I&#x003ba;B&#x003b1;)-regulated and the alternative p100-regulated pathway that result in the activation of p50-RelA and p52-RelB NF-&#x003ba;B heterodimers, respectively.</p></sec><sec><title>Results</title><p>Using microarray analysis, we investigated the transcriptional response downstream of the LT&#x003b2;R in mouse embryonic fibroblasts (MEFs) and its regulation by the RelA and RelB subunits of NF-&#x003ba;B. We describe novel LT&#x003b2;R-responsive genes that were regulated by RelA and/or RelB. The majority of LT&#x003b2;R-regulated genes required the presence of both RelA and RelB, revealing significant crosstalk between the two NF-&#x003ba;B activation pathways. Gene Ontology (GO) analysis confirmed that LT&#x003b2;R-NF-&#x003ba;B target genes are predominantly involved in the regulation of immune responses. However, other biological processes, such as apoptosis/cell death, cell cycle, angiogenesis, and taxis were also regulated by LT&#x003b2;R signaling. Moreover, LT&#x003b2;R activation inhibited expression of a key adipogenic transcription factor, peroxisome proliferator activated receptor-&#x003b3; (<italic>pparg</italic>), suggesting that LT&#x003b2;R signaling may interfere with adipogenic differentiation.</p></sec><sec><title>Conclusion</title><p>Microarray analysis of LT&#x003b2;R-stimulated fibroblasts provided comprehensive insight into the transcriptional response of LT&#x003b2;R signaling and its regulation by the NF-&#x003ba;B family members RelA and RelB.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>NF-&#x003ba;B transcription factors are essential for innate and adaptive immunity, cell survival, cellular stress responses, development and maintenance of lymphoid organ structures, and other biological functions [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. The vertebrate NF-&#x003ba;B family includes five structurally related members, the Rel proteins RelA (p65), RelB, cRel, and the NF-&#x003ba;B proteins p50 and p52. Among the Rel/NF-&#x003ba;B family, only RelA, RelB, and cRel contain C-terminal transcriptional activation domains enabling them to directly regulate transcription. The other two members, p50 and p52, are synthesized as p105 and p100 precursors, respectively. The Rel and NF-&#x003ba;B proteins can form different homo- and heterodimers (for example p50-RelA or p52-RelB) that bind to DNA target sites, so-called &#x003ba;B sites. In resting cells, Rel/NF-&#x003ba;B proteins associate with inhibitory &#x003ba;B molecules (I&#x003ba;Bs) and are retained in the cytoplasm as inactive forms [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Two major NF-&#x003ba;B signaling pathways can be distinguished, the classical or canonical and the alternative or non-canonical pathway. In response to stimulation of transmembrane receptors like tumor necrosis factor receptor (TNFR)-1 or Toll-like receptor (TLR)-4, signaling cascades are initiated that lead to the liberation of Rel/NF-&#x003ba;B complexes from their I&#x003ba;B molecules. As a result, they translocate to the nucleus and regulate transcription of numerous target genes. This classical pathway involves phosphorylation of I&#x003ba;B&#x003b1; by the NEMO (NF-&#x003ba;B essential modulator)/IKK&#x003b3;- and IKK&#x003b2;-containing I&#x003ba;B kinase (IKK) complex followed by its ubiquitin-dependent proteasomal degradation. Regulation of gene transcription is predominantly mediated through p50-RelA and p50-cRel heterodimers and target genes are mainly involved in innate immunity, cell survival, and inflammation. A few inducers of NF-&#x003ba;B, like LT&#x003b2;R, are able to trigger an additional, so-called alternative or non-canonical pathway through the activation of NF-&#x003ba;B-inducing kinase (NIK) and IKK&#x003b1;. The alternative pathway governs gene regulation mainly through p52-RelB heterodimers that are generated from the inactive cytoplasmic p100-RelB complex via signal-dependent processing of the p100 inhibitor to p52. This pathway controls genes that are predominantly involved in adaptive immunity and lymphoid organ development [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Recent findings by Hoffmann and colleagues extend this scenario. They could show that not only RelB- but also RelA-containing complexes can be released from the p100 inhibitor after LT&#x003b2;R stimulation [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p><p>This report focuses on the transcriptional response downstream of the LT&#x003b2;R and its regulation by RelA and RelB. The role of LT&#x003b2;R signaling in development and organization of secondary lymphoid structures is well documented (reviewed in [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]). We are interested in similarities and differences in RelA and RelB function in lymphoid organ development. However, a major problem is that RelA-deficient (<italic>relA</italic><sup>-/-</sup>) mice are embryonic lethal due to tumor necrosis factor (TNF)-induced hepatocyte apoptosis [<xref ref-type="bibr" rid="B18">18</xref>]. Moreover, RelB-deficient (<italic>relB</italic><sup>-/-</sup>) mice display impaired secondary lymphoid organ development and suffer from an autoinflammatory syndrome that also affects organization and function of lymphoid tissues [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Thus, stromal compartments that display LT&#x003b2;R signaling and thereby have an organizational role in the development of lymphoid organs cannot be used for <italic>in vivo </italic>gene expression studies from the above animals. Therefore, we applied MEFs established from wild-type (wt), <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/- </sup>mice as an <italic>in vitro </italic>model system. Also, there is increasing evidence that LT&#x003b2;R functions beyond lymphoid organs, as it is involved in liver regeneration, hepatitis [<xref ref-type="bibr" rid="B21">21</xref>], and hepatic lipid metabolism [<xref ref-type="bibr" rid="B22">22</xref>]. We therefore hypothesized that LT&#x003b2;R signaling, via RelA and/or RelB, may participate in physiological processes other than lymphorganogenesis. MEFs with different genotypes (wt, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/-</sup>) allowed us to dissect specific RelA and RelB activities in the regulation of gene transcription after LT&#x003b2;R stimulation. In wt MEFs, LT&#x003b2;R signals were predominantly transduced by RelA- and/or RelB-containing dimers. Upon LT&#x003b2;R signaling in <italic>relA</italic><sup>-/- </sup>cells, gene regulatory events were mediated by RelB and <italic>vice versa </italic>in <italic>relB</italic><sup>-/- </sup>cells, changes in gene expression were mediated by RelA. Using this system, we describe novel LT&#x003b2;R-responsive genes that were regulated solely by RelA or RelB or by both RelA and RelB.</p></sec><sec><title>Results and discussion</title><sec><title>LT&#x003b2;R stimulation of MEFs</title><p>For LT&#x003b2;R stimulation, MEFs of each genotype were either left untreated or were treated with agonistic anti-LT&#x003b2;R monoclonal antibody (mAb) for 2.5 or 10 h. For each treatment group, cells from four experiments were pooled. Nuclear protein extracts were used in electrophoretic mobility shift assays (EMSAs) to verify proper LT&#x003b2;R signaling (Figure <xref ref-type="fig" rid="F1">1</xref>). In wt cells, LT&#x003b2;R signaling resulted in modest induction of &#x003ba;B-binding complexes at the early time point (2.5 h) but strong induction after 10 h of stimulation. Dissection of these complexes with supershifting antibodies revealed that the faster migrating complex contained RelB and the slower migrating complex contained RelA. As expected, in wt cells both RelA and RelB complexes were activated in response to LT&#x003b2;R signaling, whereas in <italic>relA</italic><sup>-/- </sup>cells only RelB- and in <italic>relB</italic><sup>-/- </sup>cells only RelA-containing &#x003ba;B-binding complexes were induced (Figure <xref ref-type="fig" rid="F1">1</xref>). Recently, slow and relatively weak DNA-binding of NF-&#x003ba;B complexes in response to LT&#x003b2;R ligation was reported [<xref ref-type="bibr" rid="B12">12</xref>]. The plateau was reached between 10 and 15 h of LT&#x003b2;R stimulation corresponding to a 2- to 3-fold induction of NF-&#x003ba;B DNA binding. Our results are in agreement with these observations: for each genotype the strongest induction of &#x003ba;B-binding complexes was observed at 10 h. For gene expression profiling we therefore used total RNA isolated from untreated (0 h) and 10 h agonistic anti-LT&#x003b2;R mAb treated wt, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/- </sup>MEFs, assuming that stronger DNA-binding activity reflects stronger gene expression changes controlled by NF-&#x003ba;B transcription factor complexes.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Confirmation of LT&#x003b2;R stimulation: induction of RelA- and RelB-containing DNA-binding complexes</bold>. Wild-type, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/- </sup>MEFs were treated with agonistic anti-LT&#x003b2;R mAb for the indicated times and subsequently nuclear extracts were prepared and analyzed by EMSA for NF-&#x003ba;B DNA-binding activity using an Ig&#x003ba; oligo. Specific Ig&#x003ba; DNA-binding complexes are indicated by arrow (RelA-containing dimers) and arrowhead (RelB-containing dimers). Non-specific DNA binding complexes (ns, lower lane) serve as loading control. Supershift analysis was performed using pre-immune serum (pre-imm. serum), anti-RelA antibody (&#x003b1;-RelA Ab), and anti-RelB antibody (&#x003b1;-RelB Ab). Supershifted complexes are indicated by asterisk.</p></caption><graphic xlink:href="1471-2164-9-606-1"/></fig></sec><sec><title>Global gene expression in response to LT&#x003b2;R stimulation in MEFs</title><p>To identify RelA- and RelB-regulated genes after LT&#x003b2;R stimulation, we carried out microarray analysis using total RNA from the experiment described above hybridized to CodeLink UniSet Mouse 20K I bioarrays. For statistical analysis, different genotypes were analyzed separately and significantly differentially expressed genes between time points 0 h and 10 h were identified (<italic>p </italic>&#x0003c; 0.05). The fold change (FC) threshold was determined from the minimal detectable fold change (MDFC) calculated by the CodeLink Expression Analysis v4.1 software (wt: 1.48; <italic>relA</italic><sup>-/-</sup>: 1.54; <italic>relB</italic><sup>-/-</sup>: 1.36). In response to LT&#x003b2;R stimulation, a total of 528 genes were regulated in wt cells. In line with the moderate NF-&#x003ba;B activation seen in the EMSAs the observed gene regulation was also modest: gene expression changes were in the range of +5-fold (induction) and -5-fold (repression). We assigned the 528 LT&#x003b2;R-responsive genes to 4 categories: genes that were significantly regulated (i) only in wt cells (category I, n = 366), (ii) in wt and <italic>relA</italic><sup>-/- </sup>cells (category II, n = 30), (iii) in wt and <italic>relB</italic><sup>-/- </sup>cells (category III, n = 102), and (iv) genes that were significantly regulated in all 3 genotypes (category IV, n = 30) (Figure <xref ref-type="fig" rid="F2">2A</xref>; for the list of LT&#x003b2;R-responsive genes in wt cells see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>LT&#x003b2;R-responsive genes can be allocated into distinct categories</bold>. (A) Venn-diagram of significantly (<italic>p </italic>&#x0003c; 0.05) regulated genes. (B) Schematic depiction of gene expression patterns. The four main categories in (A) can be segregated into further subcategories, depending on whether their genes were upregulated or downregulated. The arrows in the plots show the direction of gene expression changes from non-induced (0 h) to the 10 h induced state in response to LT&#x003b2;R stimulation. The first arrow describes gene expression behavior in wild-type, the second in <italic>relA</italic><sup>-/-</sup>, and the third in <italic>relB</italic><sup>-/- </sup>cells. Horizontal arrows indicate lack of change or statistically insignificant change in gene expression. Arrows pointing upwards or downwards indicate significant positive or negative regulation, respectively.</p></caption><graphic xlink:href="1471-2164-9-606-2"/></fig><p>The genes in these four categories could be segregated into further subcategories, which helped us to assign regulatory mechanisms underlying the expression patterns of individual genes (see schematic depiction of gene expression behavior in Figure <xref ref-type="fig" rid="F2">2B</xref> and lists of genes belonging to different subcategories in Additional files <xref ref-type="supplementary-material" rid="S2">2</xref>, <xref ref-type="supplementary-material" rid="S3">3</xref>, <xref ref-type="supplementary-material" rid="S4">4</xref>, <xref ref-type="supplementary-material" rid="S5">5</xref>).</p><p>Category (cat) I genes were significantly regulated only in wt cells in response to LT&#x003b2;R stimulation. This group of genes required both RelA and RelB for their LT&#x003b2;R-dependent activation (cat I/1, n = 161) or repression (cat I/2, n = 205). Therefore, expression of these genes did not significantly change in either of the mutant cell lines in response to agonistic anti-LT&#x003b2;R mAb treatment (Figure <xref ref-type="fig" rid="F2">2B</xref>, Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>Category II genes were significantly regulated in wt and <italic>relA</italic><sup>-/- </sup>cells upon LT&#x003b2;R ligation. Genes upregulated (cat II/1, n = 13) or downregulated (cat II/2, n = 17) in both wt and <italic>relA</italic><sup>-/- </sup>cells, but not significantly regulated in <italic>relB</italic><sup>-/- </sup>cells, were considered to be RelB target genes in response to LT&#x003b2;R signaling. Other theoretical patterns could also be appointed to category II, but we did not find any example in our analysis for these subcategories (cat II/3, n = 0 and cat II/4, n = 0) (Figure <xref ref-type="fig" rid="F2">2B</xref>, Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>).</p><p>Genes belonging to category III were significantly regulated in wt and <italic>relB</italic><sup>-/- </sup>cells in response to LT&#x003b2;R stimulation. Genes upregulated (cat III/1, n = 54) or downregulated (cat III/2, n = 43) in both wt and <italic>relB</italic><sup>-/- </sup>cells, but not significantly regulated in <italic>relA</italic><sup>-/- </sup>cells, were considered to be RelA target genes in response to LT&#x003b2;R signaling. Negligible numbers of genes in category III could also be allocated to cat III/3 and III/4 (n = 3 and n = 2, respectively) (Figure <xref ref-type="fig" rid="F2">2B</xref>, Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>). However, these genes were not further analyzed. The significantly larger number of RelA- (cat III) compared to RelB-regulated genes (cat II; Figure <xref ref-type="fig" rid="F2">2A</xref>) is likely to be a consequence of the stronger LT&#x003b2;R-induced DNA binding of RelA compared to RelB complexes (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>Category IV genes were significantly regulated in each of the genotypes in response to LT&#x003b2;R ligation. Although eight theoretically possible gene expression behaviors exist, we only found genes that belonged to two easily explainable scenarios: genes were either upregulated (cat IV/1, n = 20), or downregulated (cat IV/2, n = 10) in each genotype upon LT&#x003b2;R signaling (Figure <xref ref-type="fig" rid="F2">2B</xref>, Additional file <xref ref-type="supplementary-material" rid="S5">5</xref>). Most likely, both RelA and RelB contributed redundantly to their regulation or alternatively, a third factor/pathway controlled these genes in response to LT&#x003b2;R stimulation. JNK (c-Jun N-terminal kinase) is a possible candidate for such a third pathway, as there are indications that LT&#x003b2;R stimulation leads to activation of JNK. However, the experimental setup in those studies was different from ours as LT&#x003b2;R-overexpressing HEK293 cells [<xref ref-type="bibr" rid="B23">23</xref>] or treatment of MEFs with the LT&#x003b2;R agonist LIGHT (lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells) [<xref ref-type="bibr" rid="B24">24</xref>] were studied.</p><p>FC values observed in the three cell lines at 10 h compared to 0 h are displayed in a heatmap that also reflects the four categories and their subcategories (Figure <xref ref-type="fig" rid="F3">3</xref>, for a zoomable/enlarged version of FC heatmaps supplied with gene symbols and GenBank Accession Numbers see Additional file <xref ref-type="supplementary-material" rid="S6">6</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Fold change heatmaps</bold>. Heatmaps displaying the fold change values observed in the three different cell lines at 10 h compared to 0 h. The color code indicates the fold change values between -2.5-fold downregulation (green) and +2.5-fold upregulation (red). Fold change of -2.5 and below are depicted in the brightest green and fold change of +2.5 and above are shown in the brightest red. Black indicates no change in gene expression. Each horizontal line on the heatmap corresponds to one gene. Genes are arranged by their subcategory (see bars on the left) and main categories are divided by a horizontal white line.</p></caption><graphic xlink:href="1471-2164-9-606-3"/></fig><p>Interestingly, in the two subcategories with the largest number of genes both RelA and RelB together were required for LT&#x003b2;R-induced gene regulation (161 cat I/1 genes for their activation and 205 cat I/2 genes for their repression). In case one of the transcription factors was missing the other one was not able to ensure regulation alone, suggesting significant crosstalk between the two NF-&#x003ba;B activation pathways. In response to LT&#x003b2;R stimulation, sequential engagement of the classical and alternative pathway was suggested, resulting in initial DNA binding by RelA followed by RelB complexes [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. These findings may suggest a scenario where RelA binds first to the DNA in the promoter of category I genes, loosens up chromatin, thereby enabling subsequent DNA binding and gene regulatory action by RelB [<xref ref-type="bibr" rid="B25">25</xref>]. Alternatively, since <italic>relB </italic>is an NF-&#x003ba;B target gene [<xref ref-type="bibr" rid="B26">26</xref>] RelA may ensure sufficiently high expression of RelB and in the absence of RelA the reduced RelB levels cannot mediate proper regulation of certain LT&#x003b2;R target genes. This possibility is supported by the observation that in the absence of RelA both RelB protein levels and binding of RelB to &#x003ba;B sites were reduced (Figure <xref ref-type="fig" rid="F1">1</xref> and data not shown) [<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>Meta analysis of LT&#x003b2;R-dependent transcriptomes</title><p>LT&#x003b2;R signaling is best known in the context of secondary lymphoid organ development and a recent expression profiling study described LT&#x003b2;R-dependent transcriptomes in lymph nodes and follicular dendritic cells (FDCs) [<xref ref-type="bibr" rid="B27">27</xref>]. However, increasing evidence suggests that LT&#x003b2;R also plays a role in non-lymphoid organs such as epithelial tissues during embryonic development [<xref ref-type="bibr" rid="B28">28</xref>] and adult liver [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p><p>To interpret our results in the light of other studies investigating LT&#x003b2;R signaling, we compared our LT&#x003b2;R-responsive genes with two recently published LT&#x003b2;R-dependent transcriptomes. Huber <italic>et al</italic>. identified transcripts in murine mesenteric lymph nodes affected <italic>in vivo </italic>by the administration of a soluble LT&#x003b2;R-Ig decoy receptor which blocks LT&#x003b2;R signaling [<xref ref-type="bibr" rid="B27">27</xref>]. A gene cluster of 80 unique transcripts that showed decreased expression after LT&#x003b2;R blockade was further analyzed. Twelve genes in this cluster were also associated with germinal centers (GCs)/FDC. A few common genes were found between our analysis and the LT&#x003b2;R-dependent transcriptomes described by Huber <italic>et al</italic>. <italic>Dclk1 </italic>and <italic>enpp2 </italic>(doublecortin-like kinase 1; GenBank Accession Number: <ext-link ext-link-type="gen" xlink:href="NM_019978">NM_019978</ext-link> and ectonucleotide pyrophosphatase/phosphodiesterase 2 or autotaxin; GenBank Accession Number: <ext-link ext-link-type="gen" xlink:href="NM_015744">NM_015744</ext-link>) expression was moderately decreased 3 d after LT&#x003b2;R blockade (FC: 0.70&#x000d7; and 0.66&#x000d7;, respectively) [<xref ref-type="bibr" rid="B27">27</xref>]. In our hands, both genes were upregulated in response to LT&#x003b2;R stimulation in a RelA-dependent manner (cat III/1, for <italic>enpp2 </italic>see also Table <xref ref-type="table" rid="T12">12</xref>). <italic>Enpp2 </italic>was also found to be associated with GC/FDC in mesenteric lymph nodes [<xref ref-type="bibr" rid="B27">27</xref>]. Moreover, Enpp2 (also called autotaxin) has been recently described as a new molecule in lymphocyte homing through high endothelial venules (HEVs) [<xref ref-type="bibr" rid="B29">29</xref>]. Collectively, these findings suggest that LT&#x003b2;R, in addition to its well-described effect on the HEV differentiation program [<xref ref-type="bibr" rid="B30">30</xref>], further contributes via RelA-dependent upregulation of <italic>enpp2 </italic>to lymphocyte homing through HEVs. Unfortunately, we could not detect further genes with a similar regulation pattern in our and Huber and colleagues' studies. This lack of overlap could be the consequence of several reasons: (i) different modes of function and kinetics of antagonistic LT&#x003b2;R-Ig vs agonistic anti-LT&#x003b2;R mAb application, (ii) incubation time (3 d treatment with LT&#x003b2;R-Ig vs 10 h treatment with agonistic anti-LT&#x003b2;R mAb), or (iii) <italic>in vivo </italic>collection of different cell types influenced by the treatment vs <italic>in vitro </italic>cell culture system using MEFs.</p><p>Lo <italic>et al</italic>. described a hepatic gene expression profile of wt vs lck-LIGHT transgenic mice (overexpressing the LT&#x003b2;R ligand LIGHT on the surface of T lymphocytes) [<xref ref-type="bibr" rid="B22">22</xref>]. A group of significantly regulated genes (n = 19) involved in lipid and cholesterol metabolism was identified. The gene that displayed the highest level of regulation (23-fold repression in transgenic vs wt mice) encodes for hepatic lipase, a key enzyme in lipid metabolism. We did not observe repression of hepatic lipase in our experiments, most probably due to its restricted expression on the surface of hepatocytes. However, we found another gene belonging to the lipid/cholesterol metabolism-related group described by Lo and colleagues. <italic>Ralgds </italic>(ral guanine nucleotide dissociation stimulator, GenBank Accession Number: <ext-link ext-link-type="gen" xlink:href="NM_009058">NM_009058</ext-link>) expression was increased in the liver of transgenic mice and also upregulated in our LT&#x003b2;R stimulation experiments, belonging to the RelA-responsive genes (cat III/1, Table <xref ref-type="table" rid="T12">12</xref>).</p></sec><sec><title>Gene Ontology (GO) enrichment analysis</title><p>Our goal was not only to define the LT&#x003b2;R-dependent transcriptome in MEFs, but also to assign regulatory mechanisms to LT&#x003b2;R signaling, i.e. to examine which part of the LT&#x003b2;R transcriptome is regulated by RelA, RelB, or both. We started out with GO enrichment analysis of significantly regulated genes to identify biological processes, molecular functions, and cellular components putatively regulated in the categories described above. Compared to molecular functions and cellular components, GO analysis of biological processes yielded the most conclusive results.</p><p>First, GO analysis was performed on the total LT&#x003b2;R transcriptome in wt cells to see how LT&#x003b2;R signaling influences biological processes in these fibroblasts, regardless whether these genes were also regulated in <italic>relA</italic><sup>-/- </sup>or <italic>relB</italic><sup>-/- </sup>cells (Category: Total wild-type, Table <xref ref-type="table" rid="T1">1</xref>). For interpretation of our data we chose GO terms with <italic>p </italic>&#x0003c; 0.01. As lower limit, we did not consider GO terms with less than 3 annotated genes in the list of differentially regulated genes since they are too specific. As upper limit we did not use GO terms represented by more than 600 genes on the microarray since they are too general. Among the considered GO terms we found that apoptosis/cell death (A/CD)- and cell cycle (CCY)-related processes were overrepresented. We also found that genes annotated with "response to biotic stimulus", "immune system process" (immune related (IR) features) as well as "blood vessel morphogenesis" and "angiogenesis" (blood vessel development related (BR) features) were enriched. Collectively, these data indicate that LT&#x003b2;R signaling largely influences cell survival/cell proliferation features. Moreover, it has an impact on immune responses and blood vessel development/angiogenesis related processes. Since these GO terms were found in LT&#x003b2;R-stimulated "non-immune" fibroblasts it is likely that LT&#x003b2;R signaling regulates similar biological processes in stromal cells of secondary lymphoid tissues governing lymphorganogenesis and maintaining lymphoid tissue architecture.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Gene Ontology analysis of total LT&#x003b2;R transcriptome in wild-type cells</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0007049</td><td align="left">Cell cycle</td><td align="center">CCY</td><td align="center">1.80E-05</td><td align="center">39</td><td align="center">559</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006915</td><td align="left">Apoptosis</td><td align="center">A/CD</td><td align="center">1.00E-04</td><td align="center">34</td><td align="center">499</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0008219</td><td align="left">Cell death</td><td align="center">A/CD</td><td align="center">0.00011</td><td align="center">35</td><td align="center">523</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0016265</td><td align="left">Death</td><td align="center">A/CD</td><td align="center">0.00011</td><td align="center">35</td><td align="center">523</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0012501</td><td align="left">Programmed cell death</td><td align="center">A/CD</td><td align="center">0.00012</td><td align="center">34</td><td align="center">503</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006259</td><td align="left">DNA metabolic process</td><td align="center">CCY</td><td align="center">0.00016</td><td align="center">32</td><td align="center">469</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022402</td><td align="left">Cell cycle process</td><td align="center">CCY</td><td align="center">0.00034</td><td align="center">30</td><td align="center">447</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042981</td><td align="left">Regulation of apoptosis</td><td align="center">A/CD</td><td align="center">0.00063</td><td align="center">23</td><td align="center">319</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043067</td><td align="left">Regulation of programmed cell death</td><td align="center">A/CD</td><td align="center">0.00068</td><td align="center">23</td><td align="center">321</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009607</td><td align="left">Response to biotic stimulus</td><td align="center">IR</td><td align="center">0.0035</td><td align="center">11</td><td align="center">124</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006260</td><td align="left">DNA replication</td><td align="center">CCY</td><td align="center">0.0037</td><td align="center">10</td><td align="center">107</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043066</td><td align="left">Negative regulation of apoptosis</td><td align="center">A/CD</td><td align="center">0.0045</td><td align="center">11</td><td align="center">128</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0000074</td><td align="left">Regulation of progression through cell cycle</td><td align="center">CCY</td><td align="center">0.0047</td><td align="center">19</td><td align="center">287</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043069</td><td align="left">Negative regulation of programmed cell death</td><td align="center">A/CD</td><td align="center">0.0048</td><td align="center">11</td><td align="center">129</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0051726</td><td align="left">Regulation of cell cycle</td><td align="center">CCY</td><td align="center">0.0051</td><td align="center">19</td><td align="center">289</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0002376</td><td align="left">Immune system process</td><td align="center">IR</td><td align="center">0.0053</td><td align="center">30</td><td align="center">534</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0030968</td><td align="left">Unfolded protein response</td><td></td><td align="center">0.0054</td><td align="center">3</td><td align="center">11</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007610</td><td align="left">Behavior</td><td></td><td align="center">0.0054</td><td align="center">17</td><td align="center">249</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009953</td><td align="left">Dorsal/ventral pattern formation</td><td></td><td align="center">0.0057</td><td align="center">5</td><td align="center">37</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0016567</td><td align="left">Protein ubiquitination</td><td></td><td align="center">0.0064</td><td align="center">5</td><td align="center">35</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006730</td><td align="left">One-carbon compound metabolic process</td><td></td><td align="center">0.0067</td><td align="center">7</td><td align="center">65</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048514</td><td align="left">Blood vessel morphogenesis</td><td align="center">BR</td><td align="center">0.0078</td><td align="center">12</td><td align="center">157</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0040029</td><td align="left">Regulation of gene expression, epigenetic</td><td></td><td align="center">0.0082</td><td align="center">5</td><td align="center">37</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007631</td><td align="left">Feeding behavior</td><td></td><td align="center">0.0084</td><td align="center">4</td><td align="center">24</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0001525</td><td align="left">Angiogenesis</td><td align="center">BR</td><td align="center">0.0087</td><td align="center">10</td><td align="center">121</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006171</td><td align="left">cAMP biosynthetic process</td><td></td><td align="center">0.0089</td><td align="center">3</td><td align="center">13</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0051094</td><td align="left">Positive regulation of developmental process</td><td></td><td align="center">0.0092</td><td align="center">6</td><td align="center">53</td></tr></tbody></table><table-wrap-foot><p>Analysis of functional enrichment was performed employing Fisher's exact test. The number of genes annotated with a specific GO term was determined for the list of differentially expressed genes (n sel.) and compared to all GO annotated genes on the array (n tot.). The resulting <italic>p </italic>values (<italic>p </italic>&#x0003c; 0.01) were used to rank GO terms according to their significance. Terms with more than 600 genes on the array or less than 3 genes on the list of investigated genes were regarded as too general or too specific, respectively, and excluded from the analysis. A/CD, apoptosis/cell death; CCY, cell cycle; IR, immune related; BR, blood vessel development related.</p></table-wrap-foot></table-wrap><p>Next, we carried out GO analysis for the four main categories and for all subcategories with at least 20 genes. Interpretation of the data was performed applying the same criteria as above. GO analysis of category I genes revealed those biological processes that were overrepresented only in LT&#x003b2;R-stimulated wt cells, i.e. in the presence of both RelA and RelB (Table <xref ref-type="table" rid="T2">2</xref>). Amongst these processes, CCY-related terms dominated. Subsequently, we analyzed cat I/1 (containing genes that were upregulated exclusively in wt cells) and found enrichment of IR- and cell/biological adhesion (important events in immune cell migration)-related terms on the list of biological processes (Table <xref ref-type="table" rid="T3">3</xref>). This finding indicates that in the absence of RelA or RelB a considerable portion of LT&#x003b2;R-stimulated immune response-related events cannot be carried out; fibroblasts need both molecules to execute these processes. In cat I/2 (containing genes that are downregulated exclusively in wt cells) we found enrichment of CCY-related terms on the list of overrepresented biological processes (Table <xref ref-type="table" rid="T4">4</xref>). This finding indicates that in wt cells an important action of RelA and RelB is to downregulate numerous genes that are implicated in cell cycle regulation in response to LT&#x003b2;R signaling.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Gene Ontology analysis of category I</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0006259</td><td align="left">DNA metabolic process</td><td align="center">CCY</td><td align="center">1.40E-05</td><td align="center">27</td><td align="center">469</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007049</td><td align="left">Cell cycle</td><td align="center">CCY</td><td align="center">1.80E-05</td><td align="center">30</td><td align="center">559</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022402</td><td align="left">Cell cycle process</td><td align="center">CCY</td><td align="center">0.00033</td><td align="center">23</td><td align="center">447</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0040029</td><td align="left">Regulation of gene expression, epigenetic</td><td></td><td align="center">0.0016</td><td align="center">5</td><td align="center">37</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006260</td><td align="left">DNA replication</td><td align="center">CCY</td><td align="center">0.0036</td><td align="center">8</td><td align="center">107</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022403</td><td align="left">Cell cycle phase</td><td align="center">CCY</td><td align="center">0.0041</td><td align="center">12</td><td align="center">211</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006730</td><td align="left">One-carbon compound metabolic process</td><td></td><td align="center">0.0041</td><td align="center">6</td><td align="center">65</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0051301</td><td align="left">Cell division</td><td align="center">CCY</td><td align="center">0.0045</td><td align="center">11</td><td align="center">187</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0031497</td><td align="left">Chromatin assembly</td><td></td><td align="center">0.0047</td><td align="center">5</td><td align="center">47</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0016458</td><td align="left">Gene silencing</td><td></td><td align="center">0.0068</td><td align="center">3</td><td align="center">17</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009953</td><td align="left">Dorsal/ventral pattern formation</td><td></td><td align="center">0.0079</td><td align="center">4</td><td align="center">34</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043543</td><td align="left">Protein amino acid acylation</td><td></td><td align="center">0.008</td><td align="center">3</td><td align="center">18</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0000278</td><td align="left">Mitotic cell cycle</td><td align="center">CCY</td><td align="center">0.0081</td><td align="center">10</td><td align="center">175</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0016567</td><td align="left">Protein ubiquitination</td><td></td><td align="center">0.0087</td><td align="center">4</td><td align="center">35</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. CCY, cell cycle.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Gene Ontology analysis of category I/1</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0045087</td><td align="left">Innate immune response</td><td align="center">IR</td><td align="center">0.0027</td><td align="center">4</td><td align="center">58</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0002526</td><td align="left">Acute inflammatory response</td><td align="center">IR</td><td align="center">0.0037</td><td align="center">4</td><td align="center">63</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007155</td><td align="left">Cell adhesion</td><td align="center">IR</td><td align="center">0.0054</td><td align="center">11</td><td align="center">447</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022610</td><td align="left">Biological adhesion</td><td align="center">IR</td><td align="center">0.0054</td><td align="center">11</td><td align="center">447</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. IR, immune related.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Gene Ontology analysis of category I/2</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0007049</td><td align="left">Cell cycle</td><td align="center">CCY</td><td align="center">3.10E-07</td><td align="center">24</td><td align="center">559</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006259</td><td align="left">DNA metabolic process</td><td align="center">CCY</td><td align="center">9.50E-07</td><td align="center">21</td><td align="center">469</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022402</td><td align="left">Cell cycle process</td><td align="center">CCY</td><td align="center">7.00E-06</td><td align="center">19</td><td align="center">447</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022403</td><td align="left">Cell cycle phase</td><td align="center">CCY</td><td align="center">2.40E-05</td><td align="center">12</td><td align="center">211</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0051301</td><td align="left">Cell division</td><td align="center">CCY</td><td align="center">3.90E-05</td><td align="center">11</td><td align="center">187</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0000278</td><td align="left">Mitotic cell cycle</td><td align="center">CCY</td><td align="center">0.00011</td><td align="center">10</td><td align="center">175</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006730</td><td align="left">One-carbon compound metabolic process</td><td></td><td align="center">0.00022</td><td align="center">6</td><td align="center">65</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006468</td><td align="left">Protein amino acid phosphorylation</td><td></td><td align="center">0.00025</td><td align="center">17</td><td align="center">487</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006260</td><td align="left">DNA replication</td><td align="center">CCY</td><td align="center">0.00055</td><td align="center">7</td><td align="center">107</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0000279</td><td align="left">M phase</td><td align="center">CCY</td><td align="center">0.00057</td><td align="center">9</td><td align="center">176</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0016310</td><td align="left">Phosphorylation</td><td></td><td align="center">0.00076</td><td align="center">17</td><td align="center">536</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009953</td><td align="left">Dorsal/ventral pattern formation</td><td></td><td align="center">0.001</td><td align="center">4</td><td align="center">34</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0040029</td><td align="left">Regulation of gene expression, epigenetic</td><td></td><td align="center">0.0014</td><td align="center">4</td><td align="center">37</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007067</td><td align="left">Mitosis</td><td align="center">CCY</td><td align="center">0.0015</td><td align="center">7</td><td align="center">126</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0000087</td><td align="left">M phase of mitotic cell cycle</td><td align="center">CCY</td><td align="center">0.0015</td><td align="center">7</td><td align="center">127</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043543</td><td align="left">Protein amino acid acylation</td><td></td><td align="center">0.0016</td><td align="center">3</td><td align="center">18</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007224</td><td align="left">Smoothened signaling pathway</td><td></td><td align="center">0.0038</td><td align="center">3</td><td align="center">24</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006913</td><td align="left">Nucleocytoplasmic transport</td><td></td><td align="center">0.004</td><td align="center">5</td><td align="center">79</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0051169</td><td align="left">Nuclear transport</td><td></td><td align="center">0.004</td><td align="center">5</td><td align="center">79</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007178</td><td align="left">Transmembrane receptor protein serine/threonine kinase signaling pathway</td><td></td><td align="center">0.0083</td><td align="center">4</td><td align="center">60</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0022613</td><td align="left">Ribonucleoprotein complex biogenesis and assembly</td><td></td><td align="center">0.0093</td><td align="center">6</td><td align="center">135</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0035295</td><td align="left">Tube development</td><td></td><td align="center">0.0096</td><td align="center">6</td><td align="center">136</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. CCY, cell cycle.</p></table-wrap-foot></table-wrap><p>Since cat II/1 and II/2 had only few genes (n = 13 and n = 17, respectively), investigation of GO terms for these groups of genes was not meaningful. GO analysis of the main category II (containing genes that were regulated &#x02013; either up or down &#x02013; in wt and <italic>relA</italic><sup>-/- </sup>cells, n = 30) revealed only one enriched GO term, the cell cycle (Table <xref ref-type="table" rid="T5">5</xref>). Thus, in response to LT&#x003b2;R signaling a characteristic feature of RelB was to influence cell cycle-related events.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Gene Ontology analysis of category II</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0007049</td><td align="left">Cell cycle</td><td align="center">CCY</td><td align="center">0.0059</td><td align="center">5</td><td align="center">559</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. CCY, cell cycle.</p></table-wrap-foot></table-wrap><p>Category III contains genes that were regulated &#x02013; either up or down &#x02013; in wt and <italic>relB</italic><sup>-/- </sup>cells in response to LT&#x003b2;R stimulation. Among enriched biological processes, the new and in previous categories not yet observed theme taxis and response to external/chemical stimulus (T) dominated, but A/CD-related events also appeared (Table <xref ref-type="table" rid="T6">6</xref>). As expected, the theme IR was also represented among the enriched biological processes. This shows that RelA is not only a signal transducer for immune responses and apoptosis/cell death, but also has an impact on the transcription of taxis- and stimulus-responsive genes following LT&#x003b2;R ligation. Among the enriched biological processes of cat III/1 we observed again overrepresentation of T and IR processes (Table <xref ref-type="table" rid="T7">7</xref>), revealing that in response to LT&#x003b2;R signaling RelA strongly influenced these events via upregulation of several genes. In cat III/2 we found genes that were repressed by RelA. In this subcategory RelA on one hand regulated several BR events. On the other hand, it turned out to be a negative regulator of genes involved in ion homeostasis (ION) downstream of the LT&#x003b2;R (Table <xref ref-type="table" rid="T8">8</xref>).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Gene Ontology analysis of category III</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0006939</td><td align="left">Smooth muscle contraction</td><td></td><td align="center">0.00018</td><td align="center">3</td><td align="center">16</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048675</td><td align="left">Axon extension</td><td></td><td align="center">0.00027</td><td align="center">3</td><td align="center">18</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006935</td><td align="left">Chemotaxis</td><td align="center">T</td><td align="center">0.00058</td><td align="center">5</td><td align="center">95</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042330</td><td align="left">Taxis</td><td align="center">T</td><td align="center">0.00058</td><td align="center">5</td><td align="center">95</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009605</td><td align="left">Response to external stimulus</td><td align="center">T</td><td align="center">0.0011</td><td align="center">9</td><td align="center">364</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006936</td><td align="left">Muscle contraction</td><td></td><td align="center">0.0011</td><td align="center">4</td><td align="center">64</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007610</td><td align="left">Behavior</td><td align="center">T</td><td align="center">0.002</td><td align="center">7</td><td align="center">249</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048858</td><td align="left">Cell projection morphogenesis</td><td></td><td align="center">0.003</td><td align="center">6</td><td align="center">200</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0032990</td><td align="left">Cell part morphogenesis</td><td></td><td align="center">0.003</td><td align="center">6</td><td align="center">200</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0030030</td><td align="left">Cell projection organization and biogenesis</td><td></td><td align="center">0.003</td><td align="center">6</td><td align="center">200</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007626</td><td align="left">Locomotory behavior</td><td align="center">T</td><td align="center">0.0072</td><td align="center">5</td><td align="center">169</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042981</td><td align="left">Regulation of apoptosis</td><td align="center">A/CD</td><td align="center">0.0077</td><td align="center">7</td><td align="center">319</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0043067</td><td align="left">Regulation of programmed cell death</td><td align="center">A/CD</td><td align="center">0.0079</td><td align="center">7</td><td align="center">321</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042221</td><td align="left">Response to chemical stimulus</td><td align="center">T</td><td align="center">0.0082</td><td align="center">7</td><td align="center">323</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006915</td><td align="left">Apoptosis</td><td align="center">A/CD</td><td align="center">0.009</td><td align="center">9</td><td align="center">499</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0012501</td><td align="left">Programmed cell death</td><td align="center">A/CD</td><td align="center">0.0094</td><td align="center">9</td><td align="center">503</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048522</td><td align="left">Positive regulation of cellular process</td><td></td><td align="center">0.0096</td><td align="center">10</td><td align="center">596</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006955</td><td align="left">Immune response</td><td align="center">IR</td><td align="center">0.0097</td><td align="center">7</td><td align="center">334</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. T, taxis, response to external/chemical stimulus; A/CD, apoptosis/cell death; IR, immune related.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Gene Ontology analysis of category III/1</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0006955</td><td align="left">Immune response</td><td align="center">IR</td><td align="center">2.00E-04</td><td align="center">7</td><td align="center">334</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009605</td><td align="left">Response to external stimulus</td><td align="center">T</td><td align="center">0.00034</td><td align="center">7</td><td align="center">364</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006935</td><td align="left">Chemotaxis</td><td align="center">T</td><td align="center">0.00041</td><td align="center">4</td><td align="center">95</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042330</td><td align="left">Taxis</td><td align="center">T</td><td align="center">0.00041</td><td align="center">4</td><td align="center">95</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0002376</td><td align="left">Immune system process</td><td align="center">IR</td><td align="center">0.00065</td><td align="center">8</td><td align="center">534</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007610</td><td align="left">Behavior</td><td align="center">T</td><td align="center">0.0022</td><td align="center">5</td><td align="center">249</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007626</td><td align="left">Locomotory behavior</td><td align="center">T</td><td align="center">0.0035</td><td align="center">4</td><td align="center">169</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006954</td><td align="left">Inflammatory response</td><td align="center">IR</td><td align="center">0.0036</td><td align="center">4</td><td align="center">171</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006952</td><td align="left">Defense response</td><td align="center">IR</td><td align="center">0.0052</td><td align="center">5</td><td align="center">305</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0002252</td><td align="left">Immune effector process</td><td align="center">IR</td><td align="center">0.0064</td><td align="center">3</td><td align="center">102</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042221</td><td align="left">Response to chemical stimulus</td><td align="center">T</td><td align="center">0.0066</td><td align="center">5</td><td align="center">323</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. IR, immune related; T, taxis, response to external/chemical stimulus.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T8"><label>Table 8</label><caption><p>Gene Ontology analysis of category III/2</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0006939</td><td align="left">Smooth muscle contraction</td><td></td><td align="center">1.40E-05</td><td align="center">3</td><td align="center">16</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006936</td><td align="left">Muscle contraction</td><td></td><td align="center">3.90E-05</td><td align="center">4</td><td align="center">64</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0001525</td><td align="left">Angiogenesis</td><td align="center">BR</td><td align="center">0.00046</td><td align="center">4</td><td align="center">121</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048514</td><td align="left">Blood vessel morphogenesis</td><td align="center">BR</td><td align="center">0.0012</td><td align="center">4</td><td align="center">157</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048646</td><td align="left">Anatomical structure formation</td><td align="center">BR</td><td align="center">0.0012</td><td align="center">4</td><td align="center">159</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0030005</td><td align="left">Cellular di-, tri-valent inorganic cation homeostasis</td><td align="center">ION</td><td align="center">0.0016</td><td align="center">3</td><td align="center">77</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0055066</td><td align="left">Di-, tri-valent inorganic cation homeostasis</td><td align="center">ION</td><td align="center">0.0017</td><td align="center">3</td><td align="center">78</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0008015</td><td align="left">Circulation</td><td align="center">BR</td><td align="center">0.0017</td><td align="center">3</td><td align="center">79</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0030003</td><td align="left">Cellular cation homeostasis</td><td align="center">ION</td><td align="center">0.0021</td><td align="center">3</td><td align="center">84</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0001568</td><td align="left">Blood vessel development</td><td align="center">BR</td><td align="center">0.0021</td><td align="center">4</td><td align="center">182</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0055080</td><td align="left">Cation homeostasis</td><td align="center">ION</td><td align="center">0.0021</td><td align="center">3</td><td align="center">85</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006873</td><td align="left">Cellular ion homeostasis</td><td align="center">ION</td><td align="center">0.0022</td><td align="center">3</td><td align="center">86</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0055082</td><td align="left">Cellular chemical homeostasis</td><td align="center">ION</td><td align="center">0.0022</td><td align="center">3</td><td align="center">86</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0001944</td><td align="left">Vasculature development</td><td align="center">BR</td><td align="center">0.0023</td><td align="center">4</td><td align="center">185</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0050801</td><td align="left">Ion homeostasis</td><td align="center">ION</td><td align="center">0.003</td><td align="center">3</td><td align="center">96</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0065008</td><td align="left">Regulation of biological quality</td><td></td><td align="center">0.004</td><td align="center">5</td><td align="center">354</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0065008</td><td align="left">Chemical homeostasis</td><td align="center">ION</td><td align="center">0.0062</td><td align="center">3</td><td align="center">124</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0007507</td><td align="left">Heart development</td><td align="center">BR</td><td align="center">0.0088</td><td align="center">3</td><td align="center">141</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. BR, blood vessel development related; ION, ion homeostasis.</p></table-wrap-foot></table-wrap><p>Category IV contains genes that were regulated &#x02013; either up or down &#x02013; in each of the cell types in response to LT&#x003b2;R stimulation (Table <xref ref-type="table" rid="T9">9</xref>). IR processes were overrepresented, but the terms related to hematopoietic or lymphoid organ development (LY) and taxis (T) were also present on the list of enriched biological processes. Unfortunately, we could not analyze cat IV/2, as it comprises too few genes (n = 10). Cat IV/1 contains 20 genes that were upregulated, irrespective of the genotype (Table <xref ref-type="table" rid="T10">10</xref>). These genes primarily belong to IR and T. Possibly, RelA and RelB redundantly regulate these events or alternatively a RelA- and RelB-independent third factor/pathway (e.g. JNK) controls these biological processes following LT&#x003b2;R ligation. Table <xref ref-type="table" rid="T11">11</xref> shows a summary of our GO analysis.</p><table-wrap position="float" id="T9"><label>Table 9</label><caption><p>Gene Ontology analysis of category IV</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0002376</td><td align="left">Immune system process</td><td align="center">IR</td><td align="center">4.40E-05</td><td align="center">7</td><td align="center">534</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006955</td><td align="left">Immune response</td><td align="center">IR</td><td align="center">0.00038</td><td align="center">5</td><td align="center">334</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0045595</td><td align="left">Regulation of cell differentiation</td><td></td><td align="center">0.0013</td><td align="center">3</td><td align="center">113</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006952</td><td align="left">Defense response</td><td align="center">IR</td><td align="center">0.0026</td><td align="center">4</td><td align="center">305</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042221</td><td align="left">Response to chemical stimulus</td><td align="center">T</td><td align="center">0.0032</td><td align="center">4</td><td align="center">323</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006954</td><td align="left">Inflammatory response</td><td align="center">IR</td><td align="center">0.0043</td><td align="center">3</td><td align="center">171</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0048534</td><td align="left">Hemopoietic or lymphoid organ development</td><td align="center">LY</td><td align="center">0.0064</td><td align="center">3</td><td align="center">197</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0050793</td><td align="left">Regulation of developmental process</td><td></td><td align="center">0.0067</td><td align="center">3</td><td align="center">201</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0002520</td><td align="left">Immune system development</td><td align="center">IR</td><td align="center">0.0078</td><td align="center">3</td><td align="center">212</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. IR, immune related; T, taxis, response to external/chemical stimulus; LY, hematopoietic or lymphoid organ developmental processes.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T10"><label>Table 10</label><caption><p>Gene Ontology analysis of category IV/1</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>GO number</bold></td><td align="left"><bold>GO term</bold></td><td align="center"><bold>Type of biological process</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold>n sel</bold>.</td><td align="center"><bold>n tot</bold>.</td></tr></thead><tbody><tr><td align="left">GO:0002376</td><td align="left">Immune system process</td><td align="center">IR</td><td align="center">1.40E-05</td><td align="center">6</td><td align="center">534</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006955</td><td align="left">Immune response</td><td align="center">IR</td><td align="center">2.4E-05</td><td align="center">5</td><td align="center">334</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006952</td><td align="left">Defense response</td><td align="center">IR</td><td align="center">0.00032</td><td align="center">4</td><td align="center">305</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006954</td><td align="left">Inflammatory response</td><td align="center">IR</td><td align="center">0.00091</td><td align="center">3</td><td align="center">171</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009611</td><td align="left">Response to wounding</td><td align="center">IR</td><td align="center">0.0024</td><td align="center">3</td><td align="center">240</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0015031</td><td align="left">Protein transport</td><td></td><td align="center">0.0024</td><td align="center">4</td><td align="center">523</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0045184</td><td align="left">Establishment of protein localization</td><td></td><td align="center">0.0029</td><td align="center">4</td><td align="center">546</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0008104</td><td align="left">Protein localization</td><td></td><td align="center">0.0037</td><td align="center">4</td><td align="center">586</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0042221</td><td align="left">Response to chemical stimulus</td><td align="center">T</td><td align="center">0.0056</td><td align="center">3</td><td align="center">323</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0006886</td><td align="left">Intracellular protein transport</td><td></td><td align="center">0.0057</td><td align="center">3</td><td align="center">326</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">GO:0009605</td><td align="left">Response to external stimulus</td><td align="center">T</td><td align="center">0.0078</td><td align="center">3</td><td align="center">364</td></tr></tbody></table><table-wrap-foot><p>GO analysis was performed the same way as for category "total wild-type" described in Table 1 legend. IR, immune related; T, taxis, response to external/chemical stimulus.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T11"><label>Table 11</label><caption><p>Summary of Gene Ontology analysis results</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Category/Subcategory</bold></td><td align="center"><bold>Enriched biological processes</bold></td><td align="center"><bold>Regulatory molecules downstream of LT&#x003b2;R, and their effects on the gene expression</bold></td></tr></thead><tbody><tr><td align="left">Total wild-type</td><td align="center">A/CD<break/>CCY<break/>IR<break/>BR</td><td align="center">Molecules not assignable &#x02013; up and downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat I</td><td align="center">CCY</td><td align="center">RelA and RelB together &#x02013; up and downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat I/1</td><td align="center">IR</td><td align="center">RelA and RelB together &#x02013; upregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat I/2</td><td align="center">CCY</td><td align="center">RelA and RelB together &#x02013; downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat II</td><td align="center">CCY</td><td align="center">RelB &#x02013; up and downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat II/1</td><td align="center">Not investigated</td><td align="center">RelB &#x02013; upregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat II/2</td><td align="center">Not investigated</td><td align="center">RelB &#x02013; downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat III</td><td align="center">T<break/>A/CD<break/>IR</td><td align="center">RelA &#x02013; up and downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat III/1</td><td align="center">T<break/>IR</td><td align="center">RelA &#x02013; upregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat III/2</td><td align="center">ION<break/>BR</td><td align="center">RelA &#x02013; downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat IV</td><td align="center">IR<break/>T<break/>LY</td><td align="center">RelA and RelB via redundant effects &#x02013; up and downregulation<break/><bold>OR</bold><break/>Third pathway &#x02013; up and downregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat IV/1</td><td align="center">IR<break/>T</td><td align="center">RelA and RelB via redundant effects &#x02013; upregulation<break/><bold>OR</bold><break/>Third pathway &#x02013; upregulation</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cat IV/2</td><td align="center">Not investigated</td><td align="center">RelA and RelB via redundant effects &#x02013; downregulation<break/><bold>OR</bold><break/>Third pathway &#x02013; downregulation</td></tr></tbody></table><table-wrap-foot><p>Summary of GO analysis: categories/subcategories with their respective enriched biological processes and the assigned regulatory mechanisms are listed. A/CD, apoptosis/cell death; CCY, cell cycle; IR, immune related; BR, blood vessel development related; T, taxis, response to external/chemical stimulus; ION, ion homeostasis; LY, hematopoietic or lymphoid organ developmental processes. Since cat II/1, II/2 and cat IV/2 had only few genes (n = 13, 17 and 10, respectively) they were not investigated for GO terms.</p></table-wrap-foot></table-wrap></sec><sec><title>Verification of microarray results by qRT-PCR</title><p>The changes in mRNA levels of several known as well as novel LT&#x003b2;R-responsive genes on the microarray were confirmed by quantitative real-time reverse-transcription-PCR (qRT-PCR), using RNA from three independent LT&#x003b2;R stimulation experiments (Table <xref ref-type="table" rid="T12">12</xref>). In agreement with previous reports, we also found induction of <italic>nfkb2 </italic>[<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], <italic>ccl2/mcp1 </italic>[<xref ref-type="bibr" rid="B6">6</xref>], and <italic>ikba </italic>expression [<xref ref-type="bibr" rid="B31">31</xref>] in LT&#x003b2;R-stimulated wt fibroblasts. In addition, our data indicate that both RelA and RelB redundantly contributed to the proper regulation of these genes in response to LT&#x003b2;R stimulation. However, we did not observe LT&#x003b2;R-dependent upregulation of lymphorganogenic chemokines as described by others. <italic>Ccl21</italic>, <italic>ccl19</italic>, <italic>cxcl13</italic>, and <italic>cxcl12 </italic>were shown to be LT&#x003b2;R-induced genes in spleen 8 h after peritoneal injection of an agonistic anti-LT&#x003b2;R mAb [<xref ref-type="bibr" rid="B5">5</xref>]. Possibly, cell context-specific signaling accounts for the difference observed between splenocytes and established 3T3 fibroblasts used in our experiments. Basak <italic>et al</italic>. observed modest upregulation of <italic>cxcl13 </italic>and <italic>ccl21 </italic>in established wt 3T3 fibroblasts after 24 h treatment with agonistic anti-LT&#x003b2;R mAb [<xref ref-type="bibr" rid="B13">13</xref>]. To reduce indirect gene regulatory effects due to rather long stimulation we activated LT&#x003b2;R signaling only for 10 h, where modulation of these chemokines was not observed.</p><table-wrap position="float" id="T12"><label>Table 12</label><caption><p>Verification of microarray results by qRT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene Symbol and GenBank Accession Number</bold></td><td align="left"><bold>CodeLink bioarrays FC and <italic>p </italic>value (in brackets) for wt/<italic>relA</italic><sup>-/-</sup>/<italic>relB</italic><sup>-/- </sup>cells and corresponding subcategory</bold></td><td align="left"><bold>qRT-PCR FC &#x000b1; SD for wt/<italic>relA</italic><sup>-/-</sup>/<italic>relB</italic><sup>-/- </sup>cells and corresponding subcategory</bold></td></tr></thead><tbody><tr><td align="left"><bold>Cx3cl1</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_009142">NM_009142</ext-link></td><td align="left">1.77 (0.00370)/0.90 (&#x0003e;0.05)/0.96 (&#x0003e;0.05), <bold>I/1</bold></td><td align="left">1.66 &#x000b1; 0.22/0.89 &#x000b1; 0.10/1.08 &#x000b1; 0.29, <bold>I/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Pparg</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_011146">NM_011146</ext-link></td><td align="left">0.65 (0.00690)/0.55 (0.01800)/1.32 (&#x0003e;0.05), <bold>II/2</bold></td><td align="left">0.50 &#x000b1; 0.02/0.48 &#x000b1; 0.04/0.81 &#x000b1; 0.11, <bold>II/2</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Ralgds *<break/><ext-link ext-link-type="gen" xlink:href="NM_009058">NM_009058</ext-link></td><td align="left">2.24 (0.00750)/1.48 (&#x0003e;0.05)/1.58 (0.00140), <bold>III/1</bold></td><td align="left">2.03 &#x000b1; 0.42/1.13 &#x000b1; 0.10/1.17 &#x000b1; 0.16, <bold>I/1 &#x02013; not verified in <italic>relB</italic><sup>-/- </sup>cells</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Enpp2 *<break/><ext-link ext-link-type="gen" xlink:href="NM_015744">NM_015744</ext-link></td><td align="left">2.28 (0.00150)/1.36 (&#x0003e;0.05)/5.10 (0.00070), <bold>III/1</bold></td><td align="left">1.85 &#x000b1; 0.30/1.35 &#x000b1; 0.27/3.29 &#x000b1; 0.91, <bold>III/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Birc3<break/><ext-link ext-link-type="gen" xlink:href="NM_007464">NM_007464</ext-link></td><td align="left">2.77 (0.00090)/1.34 (&#x0003e;0.05)/2.94 (0.00140), <bold>III/1</bold></td><td align="left">2.86 &#x000b1; 0.73/1.27 &#x000b1; 0.11/2.99 &#x000b1; 0.47, <bold>III/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Cxcl10/IP10</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_021274">NM_021274</ext-link></td><td align="left">1.91 (0.00450)/0.58 (&#x0003e;0.05)/2.14 (0.03000), <bold>III/1</bold></td><td align="left">2.58 &#x000b1; 0.21/1.28 &#x000b1; 0.39/2.67 &#x000b1; 0.20, <bold>III/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Irf1<break/><ext-link ext-link-type="gen" xlink:href="NM_008390">NM_008390</ext-link></td><td align="left">1.96 (0.00270)/2.05 (&#x0003e;0.05)/2.90 (0.00075), <bold>III/1</bold></td><td align="left">2.67 &#x000b1; 0.32/1.77 &#x000b1; 0.77/2.15 &#x000b1; 0.19, <bold>III/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Cd74</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_010545">NM_010545</ext-link></td><td align="left">3.11 (0.00300)/0.82 (&#x0003e;0.05)/3.46 (0.00070), <bold>III/1</bold></td><td align="left">5.01 &#x000b1; 0.99/1.06 &#x000b1; 0.18/4.77 &#x000b1; 0.56, <bold>III/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Fosl1<break/><ext-link ext-link-type="gen" xlink:href="NM_010235">NM_010235</ext-link></td><td align="left">0.49 (0.00290)/0.86 (&#x0003e;0.05)/0.42 (0.00070), <bold>III/2</bold></td><td align="left">0.46 &#x000b1; 0.09/0.90 &#x000b1; 0.09/0.47 &#x000b1; 0.10, <bold>III/2</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Nfkb2</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_019408">NM_019408</ext-link></td><td align="left">2.18 (0.0029)/1.57 (0.0016)/1.81 (0.0007), <bold>IV/1</bold></td><td align="left">2.04 &#x000b1; 0.37/2.43 &#x000b1; 0.50/2.74 &#x000b1; 0.54, <bold>IV/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Ccl2/MCP1</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_011333">NM_011333</ext-link></td><td align="left">2.10 (0.00120)/2.84 (0.0011)/2.99 (0.00099), <bold>IV/1</bold></td><td align="left">2.29 &#x000b1; 0.42/3.18 &#x000b1; 0.13/6.31 &#x000b1; 1.63, <bold>IV/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Nfkbia/I&#x003ba;B&#x003b1;</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_010907">NM_010907</ext-link></td><td align="left">2.00 (0.00064)/2.19 (0.00270)/3.42 (0.00140), <bold>IV/1</bold></td><td align="left">1.77 &#x000b1; 0.16/2.44 &#x000b1; 0.34/3.92 &#x000b1; 0.42, <bold>IV/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Ccl7/MCP3</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_013654">NM_013654</ext-link></td><td align="left">2.22 (0.00041)/1.99 (0.04700)/4.35 (0.00140), <bold>IV/1</bold></td><td align="left">2.77 &#x000b1; 0.13/3.15 &#x000b1; 0.15/5.29 &#x000b1; 1.68, <bold>IV/1</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cxcl1/KC<break/><ext-link ext-link-type="gen" xlink:href="NM_008176">NM_008176</ext-link></td><td align="left">2.40 (0.00580)/1.77 (0.01600)/1.80 (0.00160), <bold>IV/1</bold></td><td align="left">2.40 &#x000b1; 0.46/1.31 &#x000b1; 0.61/3.41 &#x000b1; 0.88, <bold>III/1 &#x02013; not verified in <italic>relA</italic><sup>-/- </sup>cells</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Id2<break/><ext-link ext-link-type="gen" xlink:href="NM_010496">NM_010496</ext-link></td><td align="left">0.42 (0.00440)/0.60 (0.04000)/0.39 (0.00075), <bold>IV/2</bold></td><td align="left">0.47 &#x000b1; 0.11/0.75 &#x000b1; 0.05/0.57 &#x000b1; 0.14, <bold>IV/2</bold></td></tr></tbody></table><table-wrap-foot><p>qRT-PCR using RNA from 3 independent LT&#x003b2;R stimulation experiments confirmed changes in mRNA levels of several known as well as novel LT&#x003b2;R-responsive genes on the microarray. Gene names (Gene Symbol) and GenBank Accesion Numbers are shown in the first column. FC values with corresponding <italic>p </italic>values in brackets, observed in the 3 cell lines (wt; <italic>relA</italic><sup>-/-</sup>; <italic>relB</italic><sup>-/-</sup>) at 10 h with CodeLink bioarrays and corresponding subcategories (in bold) are displayed in the second column. FC values with corresponding standard deviations (SD), observed in the 3 cell lines (wt; <italic>relA</italic><sup>-/-</sup>; <italic>relB</italic><sup>-/-</sup>) at 10 h with qRT-PCR using RNA from 3 independent LT&#x003b2;R stimulation experiments and corresponding subcategories (in bold) are displayed in the third column. Genes that are discussed in chapter "Meta analysis of LT&#x003b2;R-dependent transcriptomes" are indicated by an asterisk and genes that are discussed in chapter "Verification of microarray results by qRT-PCR" are listed in bold.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T13"><label>Table 13</label><caption><p>LT&#x003b2;R responsive qRT-PCR verified genes in literature</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene Symbol and GenBank Accession Number</bold></td><td align="left"><bold>LT&#x003b2;R responsiveness</bold><break/>&#x0201e;reference&#x0201c; if known/&#x0201e;this study&#x0201c; if new</td><td align="left"><bold>In response to LT&#x003b2;R stimulation, transcription is regulated by RelA or RelB, + or - or 0 manner </bold>&#x0201e;reference&#x0201c; if known/&#x0201e;this study&#x0201c; if new</td></tr></thead><tbody><tr><td align="left"><bold>Cx3cl1</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_009142">NM_009142</ext-link></td><td align="left">This study</td><td align="left">+ regulation by RelA and RelB <bold>together</bold>, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Pparg</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_011146">NM_011146</ext-link></td><td align="left">This study</td><td align="left">0 RelA, this study<break/>- RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Ralgds *<break/><ext-link ext-link-type="gen" xlink:href="NM_009058">NM_009058</ext-link></td><td align="left">Lo <italic>et al</italic>., 2007 [<xref ref-type="bibr" rid="B22">22</xref>]</td><td align="left">Mode of regulation uncertain: RelA either alone, or together with RelB enhances Ralgds expression.</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Enpp2 *<break/><ext-link ext-link-type="gen" xlink:href="NM_015744">NM_015744</ext-link></td><td align="left">Huber <italic>et al</italic>., 2005 [<xref ref-type="bibr" rid="B27">27</xref>]</td><td align="left">+ RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Birc3<break/><ext-link ext-link-type="gen" xlink:href="NM_007464">NM_007464</ext-link></td><td align="left">This study</td><td align="left">+ RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Cxcl10/IP10</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_021274">NM_021274</ext-link></td><td align="left">Lukashev <italic>et al</italic>., 2006 [<xref ref-type="bibr" rid="B34">34</xref>]</td><td align="left">+ RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Irf1<break/><ext-link ext-link-type="gen" xlink:href="NM_008390">NM_008390</ext-link></td><td align="left">Kutsch <italic>et al</italic>., 2008 [<xref ref-type="bibr" rid="B41">41</xref>]</td><td align="left">+ RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Cd74</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_010545">NM_010545</ext-link></td><td align="left">This study</td><td align="left">+ RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Fosl1<break/><ext-link ext-link-type="gen" xlink:href="NM_010235">NM_010235</ext-link></td><td align="left">This study</td><td align="left">- RelA, this study<break/>0 RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Nfkb2</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_019408">NM_019408</ext-link>.1</td><td align="left">Dejardin <italic>et al</italic>., 2002 [<xref ref-type="bibr" rid="B5">5</xref>]<break/>Derudder <italic>et al</italic>., 2003 [<xref ref-type="bibr" rid="B6">6</xref>]</td><td align="left">+ RelA, Dejardin <italic>et al</italic>., 2002 [<xref ref-type="bibr" rid="B5">5</xref>]<break/>+ RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Ccl2/MCP1</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_011333">NM_011333</ext-link></td><td align="left">Derudder <italic>et al</italic>., 2003 [<xref ref-type="bibr" rid="B6">6</xref>]</td><td align="left">+ RelA, this study<break/>+ RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Nfkbia/I&#x003ba;B&#x003b1;</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_010907">NM_010907</ext-link></td><td align="left">Bonizzi <italic>et al</italic>., 2004 [<xref ref-type="bibr" rid="B31">31</xref>]</td><td align="left">+ RelA, this study<break/>+ RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Ccl7/MCP3</bold><break/><ext-link ext-link-type="gen" xlink:href="NM_013654">NM_013654</ext-link></td><td align="left">This study</td><td align="left">+ RelA, this study<break/>+ RelB, this study</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Cxcl1/KC<break/><ext-link ext-link-type="gen" xlink:href="NM_008176">NM_008176</ext-link></td><td align="left">This study</td><td align="left">+ RelA, this study<break/>Positive regulation by RelB is uncertain.</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">Id2<break/><ext-link ext-link-type="gen" xlink:href="NM_010496">NM_010496</ext-link></td><td align="left">This study</td><td align="left">- RelA, this study<break/>- RelB, this study</td></tr></tbody></table><table-wrap-foot><p>Genes that are discussed in chapter "Meta analysis of LT&#x003b2;R-dependent transcriptomes" are indicated by an asterisk and genes that are discussed in chapter "Verification of microarray results by qRT-PCR" are listed in bold.</p></table-wrap-foot></table-wrap><p>Importantly, we verified novel LT&#x003b2;R-responsive genes and appointed regulatory molecules to them. For a complete list of verified genes see Table <xref ref-type="table" rid="T12">12</xref>. Here, some of those verified genes are discussed in more detail.</p><p>GO analysis revealed that LT&#x003b2;R stimulation resulted in the regulation of IR processes (Table <xref ref-type="table" rid="T11">11</xref>). Except category "Total wild-type", where we could not assign regulatory molecules, in all categories where IR processes were enriched, RelA alone or together with RelB acted as a positive factor. <italic>Cx3cl1 </italic>(chemokine C-X3-C motif ligand 1/fractalkine) is one of the IR genes in cat I/1. Several studies document that NF-&#x003ba;B upregulates <italic>cx3cl1</italic>, e.g. in rat aortic endothelial cells upon interleukin-1&#x003b2; (IL-1&#x003b2;), TNF, and lipopolysaccharide treatment [<xref ref-type="bibr" rid="B32">32</xref>] or in human coronary artery smooth muscle cells [<xref ref-type="bibr" rid="B33">33</xref>]. The latter work shows that atherogenic lipids induce adhesion of artery smooth muscle cells to macrophages via the upregulation of <italic>cx3cl1 </italic>in a TNF/NF-&#x003ba;B-dependent manner. In our experiments this gene was upregulated in response to LT&#x003b2;R stimulation dependent on RelA and RelB. This data suggests that LT&#x003b2;R, via employing RelA and RelB together, may act as a proatherogenic factor.</p><p>IR- and T-related processes were also enriched in cat III and cat III/1 according to the GO analysis. <italic>Cd74/ii </italic>(invariant polypeptide of major histocompatibility complex, class II antigen-associated) and <italic>cxcl10/ip10 </italic>(chemokine C-X-C motif ligand 10/interferon-inducible protein-10) are two genes in cat III/1 and assigned to IR and T. CD74/Ii is involved in antigen processing and presentation and CXCL10 is chemotactic for monocytes and T cells. Moreover, expression of CXCL10, along with two other CXCR3-binding chemokines CXCL9 and CXCL11, can be induced in carcinoma cells by LT&#x003b2;R agonists. These chemokines function as potent chemoattractants for activated T, NK, and dendritic cells, which may contribute to antitumor immune responses [<xref ref-type="bibr" rid="B34">34</xref>]. In our experiments, expression of <italic>cd74/ii </italic>and <italic>cxcl10/ip10 </italic>was upregulated by LT&#x003b2;R signaling in wt and <italic>relB</italic><sup>-/- </sup>cells. Thus, LT&#x003b2;R signaling via RelA may (i) attract T lymphocytes and promote antigen presentation by dendritic cells in the context of MHC class II and (ii) facilitate antitumor responses against cancer cells.</p><p>As indicated by GO analysis, IR- and T-related biological processes were significantly regulated in cat IV and cat IV/1. Amongst others, genes encoding proteins that participate in innate immune responses, like <italic>ccl7/mcp3</italic>, are also represented in these groups. <italic>Ccl7/mcp3 </italic>encodes the proinflammatory chemokine C-C motif ligand 7/monocyte chemotactic protein-3. Expression of <italic>ccl7/mcp3 </italic>was upregulated by LT&#x003b2;R signaling in each of the genotypes, indicating redundant positive regulation by RelA and RelB or upregulation via another RelA- and RelB-independent pathway.</p><p>Collectively, positive regulation of the expression of proinflammatory chemokines like <italic>cx3cl1</italic>, <italic>cxcl10</italic>, <italic>ccl7 </italic>(but also others, see Table <xref ref-type="table" rid="T12">12</xref>) by LT&#x003b2;R suggests that LT&#x003b2;R signaling, besides regulating development and organization of secondary lymphoid structures, also participates in innate/inflammatory immune responses and for that primarily RelA action seems to be necessary.</p><p>Moreover, we found that LT&#x003b2;R signaling functions beyond the regulation of immune responses and organization of lymphoid structures. PPAR&#x003b3; (peroxisome proliferator activated receptor &#x003b3;) is a key-regulatory transcription factor in the process of adipocyte differentiation and activation of PPAR&#x003b3; promotes the storage of fat [<xref ref-type="bibr" rid="B35">35</xref>]. The work of Fu and colleagues suggests that LT&#x003b2;R affects lipid homeostasis by downregulating hepatic lipase expression [<xref ref-type="bibr" rid="B22">22</xref>]. Hepatic lipase is expressed on the surface of hepatocytes in the liver. It promotes receptor-mediated uptake of plasma lipoproteins that harbor triglycerides and cholesterol and specifically catalyzes hydrolysis of triglycerides, actions that are suppressed when LT&#x003b2;R signaling is switched on. Expression of <italic>pparg </italic>was negatively affected by LT&#x003b2;R signaling in wt and <italic>relA</italic><sup>-/- </sup>but not in <italic>relB</italic><sup>-/- </sup>cells (belonging to cat II/2 genes), indicating that this gene was downregulated by RelB in response to LT&#x003b2;R stimulation. Our finding is a further indication that LT&#x003b2;R signaling represses lipogenesis and it may do so via RelB. It has been shown that ligand-induced transactivation by PPAR&#x003b3; is suppressed by IL-1 and TNF and that this suppression is mediated through NF-&#x003ba;B (p50-RelA) [<xref ref-type="bibr" rid="B36">36</xref>]. However, unlike suppression of PPAR&#x003b3; by p50-RelA, where this heterodimer blocks PPAR&#x003b3; binding to DNA by forming a complex with PPAR&#x003b3; and its co-activator PGC-2, LT&#x003b2;R-mediated suppression of <italic>pparg </italic>occurred via transcriptional repression executed by RelB. Further experiments are required to find out whether RelB directly or indirectly mediates repression of <italic>pparg </italic>transcription in response to LT&#x003b2;R signaling. The repressive effect of LT&#x003b2;R signaling on adipogenesis has been confirmed in MEFs that were induced for adipogenic differentiation. LT&#x003b2;R stimulation resulted in attenuated lipid droplet accumulation as well as in reduced <italic>pparg </italic>and adipogenic marker gene (<italic>fabp4/ap2</italic>) expression under conditions that promote differentiation into adipocytes (unpublished results).</p></sec></sec><sec><title>Conclusion</title><p>This study is the first systematic dissection of the RelA- and RelB-driven transcriptome response downstream of the LT&#x003b2;R. We confirmed previously described LT&#x003b2;R-regulated genes. More importantly, we identified novel LT&#x003b2;R-responsive genes and assigned underlying regulatory mechanisms executed by RelA and/or RelB to them (Table <xref ref-type="table" rid="T13">13</xref>). We found that the majority of LT&#x003b2;R-regulated genes required the presence of both RelA and RelB, suggesting significant crosstalk between the two NF-&#x003ba;B activation pathways. Gene Ontology analysis confirmed that LT&#x003b2;R-NF-&#x003ba;B target genes were predominantly involved in the regulation of immune responses. However, other biological processes such as apoptosis/cell death, cell cycle, angiogenesis, and taxis were also regulated by LT&#x003b2;R signaling. Furthermore, we show that LT&#x003b2;R stimulation downregulated expression of the gene encoding PPAR&#x003b3;, suggesting that LT&#x003b2;R signaling may repress adipogenic differentiation by attenuating the levels of this key adipogenic transcription factor. Our findings are significant since they indicate a role for LT&#x003b2;R signaling beyond immune responses and lymphoid organ development and assign underlying gene expression regulatory mechanisms to the LT&#x003b2;R transcriptome.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell culture</title><p>Mouse embryonic 3T3 fibroblasts (wild-type, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/-</sup>; kind gift from A. Hoffmann) were cultured at 37&#x000b0;C in Dulbecco's modified Eagle's medium (GIBCO/Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated bovine calf serum (Perbio Science, Bonn, Germany), penicillin (100 U/ml), streptomycin (100 &#x003bc;g/ml), and Glutamax I (2 mM) (GIBCO/Invitrogen) and treated with agonistic anti-LT&#x003b2;R mAb (1 &#x003bc;g/ml, clone AC.H6; kind gift from J. Browning and P. Rennert).</p></sec><sec><title>EMSA</title><p>Preparation of nuclear extracts and EMSAs were essentially performed as previously described [<xref ref-type="bibr" rid="B37">37</xref>]. Nuclear and cytoplasmic fractions were prepared according to standard procedures [<xref ref-type="bibr" rid="B38">38</xref>].</p></sec><sec><title>RNA isolation</title><p>Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Possible contamination by genomic DNA was removed by DNaseI treatment using the RNase-Free DNase Set (Qiagen). Quality of RNA samples was checked by spectrophotometry and agarose gel electrophoresis. RNAs (2 &#x003bc;g total RNA per sample) were used for cRNA preparation for microarrays only when the ratio A260:A280 was 1.8&#x02013;2.1 and the RNA was intact.</p></sec><sec><title>Microarrays</title><p>Microarray analysis was performed using CodeLink UniSet Mouse 20K I bioarrays (GE Healthcare, Munich, Germany), a one-color system where for each of the investigated 19,801 transcripts there is one 30&#x02013;mer oligo probe spotted per slide. For gene expression profiling, untreated (0 h) and 10 h agonistic anti-LT&#x003b2;R mAb treated wt, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/- </sup>MEFs were used. For every treatment group, cells from 4 experiments were pooled, total RNA isolated, cRNA prepared and hybridized onto the bioarrays in technical triplicates. cRNA target preparation, bioarray hybridization and detection were carried out according to the manufacturer's protocol provided with the CodeLink Expression Assay Reagent Kit. For scanning microarrays, a GenePix 4000B Array Scanner and GenePix Pro 4.0 software (Axon Instruments Inc./Molecular Devices, Munich, Germany) were employed according to settings suggested by the protocol provided with the CodeLink Expression Assay Reagent Kit. Microarray data have been deposited in NCBIs GEO <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/"/> and are accessible through GEO series accession number GSE11963.</p></sec><sec><title>Microarray data preprocessing</title><p>Microarray raw data of stimulated and unstimulated MEFs were analyzed using the Codelink&#x02122; Expression Analysis v4.1 software (GE Healthcare) and MDFC values were extracted. All subsequent analyses were performed using R and Bioconductor. For the analysis only genes with probe type 'DISCOVERY' were considered (19,801 genes) and all genes flagged MSR (Manufactory Slide Report) in any sample were excluded (leaving 19,580 genes). To remove negative expression values (local background &#x0003e; spot intensity) raw intensities with values &#x0003c; 0.01 were set to 0.01. The raw intensities of each array were scaled to the array median. After logarithmizing the expression values quantile normalization was applied across all arrays.</p></sec><sec><title>Differentially expressed genes</title><p>Array data for the different genotypes were analyzed separately. A gene was included in the analysis if it was flagged 'G' (good) or 'S' (contains saturated pixels) on at least two arrays in any of the two groups (stimulated or unstimulated). Furthermore, genes selected were required to have a FC higher than or equal to the FC threshold determined from the maximum MDFC in these groups. To identify genes significantly differentially expressed after stimulation, a Student's <italic>t</italic>-test was performed for the previously filtered genes. The resulting <italic>p </italic>values were corrected for multiple testing using the method of Benjamini and Hochberg [<xref ref-type="bibr" rid="B39">39</xref>]. Allowing a false discovery rate of 5%, a total of 528 genes were identified that were significantly regulated in wt cells (regardless whether they were regulated somewhere else). From these, 366 genes were regulated exclusively in wt, 30 genes in wt and <italic>relA</italic><sup>-/-</sup>, 102 in wt and <italic>relB</italic><sup>-/- </sup>cells and 30 genes in all 3 genotypes.</p></sec><sec><title>Functional analysis with GO</title><p>Analysis of functional enrichment was performed employing Fisher's exact test. The resulting <italic>p </italic>values (<italic>p </italic>&#x0003c; 0.01) were used to rank GO terms according to their significance. Terms with more than 600 genes on the array or less than 3 genes on the list of investigated genes were regarded as too general or too specific, respectively, and excluded from the analysis. Expert knowledge was used to assign broader themes to specific GO categories.</p></sec><sec><title>qRT-PCR</title><p>For qRT-PCR, first strand cDNA was obtained from 2 &#x003bc;g of total RNA for each treatment group using oligo-dT primers and M-MLV Reverse Transcriptase kit (Promega, Mannheim, Germany) according to manufacturer's protocols. qRT-PCRs were performed in an iCycler Thermal Cycler real-time PCR machine (Bio-Rad Laboratories, Hercules, CA) using SYBR Green I as detector dye and reagents from the Quantace SensiMix DNA Kit (Quantace Ltd., Watford, UK). Primers for qRT-PCRs with Tm of 60&#x000b0;C were designed using Primer3 software (v. 0.4.0; <ext-link ext-link-type="uri" xlink:href="http://frodo.wi.mit.edu"/>) [<xref ref-type="bibr" rid="B40">40</xref>]. For individual samples, each gene was tested in triplicates and the mean of the 3 cycle threshold values was used to calculate relative expression levels. For normalization, <italic>&#x003b2;-actin </italic>was used as an endogenous reference gene to correct for variation in RNA content and variation in the efficiency of the reverse transcription reaction. Statistical analysis of qRT-PCR results from 3 independent LT&#x003b2;R stimulation experiments was performed employing a Welch test. Forward (F) and reverse primers (R) in 5' to 3' orientation were: Nfkb2_F: GCTAATGTGAATGCCCGGAC, Nfkb2_R: CTTTGGGTATCCCTCTCAGGC, Ccl2_F: CCCACTCACCTGCTGCTACT, Ccl2_R: TCTGGACCCATTCCTTCTTG, I&#x003ba;B&#x003b1;_F: TGCACTTGGCAATCATCCAC, I&#x003ba;B&#x003b1;_R: TTCCTCGAAAGTCTCGGAGCT, Ralgds_F: CATCCACCGCCTAAAGAAGA, Ralgds_R: GGGCTCTCCTAGGGTTCATC, Cx3cl1_F: GGCTAAGCCTCAGAGCATTG, Cx3cl1_R: CATTTTCCTCTGGGGTTGA, Pparg_F: TCATGACCAGGGAGTTCCTC, Pparg_R: GGCGGTCTCCACTGAGAATA, Enpp2_F: TGGCTTACGTGACATTGAGG, Enpp2_R: GTCGGTGAGGAAGGATGAAA, Birc3_F: TGACGTGTGTGACACCAATG, Birc3_R: TGAGGTTGCTGCAGTGTTTC, Cxcl10_F: AAGTGCTGCCGTCATTTTCT, Cxcl10_R: GTGGCAATGATCTCAACACG, Irf1_F: ACCCTGGCTAGAGATGCAGA, Irf1_R: TTTGTATCGGCCTGTGTGAA, Cd74_F: ATGACCCAGGACCATGTGAT, Cd74_R: CCAGGGAGTTCTTGCTCATC, Fosl1_F: CAAAATCCCAGAAGGAGACAAG, Fosl1_R: AAAAGGAGTCAGAGAGGGTGTG, Ccl7_F: AATGCATCCACATGCTGCTA, Ccl7_R: ATAGCCTCCTCGACCCACTT, Cxcl1_F: GCTGGGATTCACCTCAAGAA, Cxcl1_R: TGGGGACACCTTTTAGCATC, Id2_F: CCCCAGAACAAGAAGGTGAC, Id2_R: ATTCAGATGCCTGCAAGGAC, &#x003b2;-actin_F: TGGCGCTTTTGACTCAGGA, &#x003b2;-actin_R: GGGAGGGTGAGGGACTTCC</p></sec></sec><sec><title>Abbreviations</title><p>LT&#x003b2;R: lymphotoxin-&#x003b2; receptor; I&#x003ba;B&#x003b1;: inhibitor of NF-&#x003ba;B &#x003b1;; MEF: mouse embryonic fibroblasts; GO: Gene Ontology; PPAR&#x003b3;/<italic>pparg</italic>: peroxisome proliferator activated receptor-&#x003b3;; TNFR1: tumor necrosis factor receptor 1; TLR4: Toll-like receptor 4; NEMO: NF-&#x003ba;B essential modulator; IKK: I&#x003ba;B kinase; NIK: NF-&#x003ba;B-inducing kinase; <italic>relA</italic><sup>-/-</sup>: RelA-deficient; TNF: tumor necrosis factor; <italic>relB</italic><sup>-/-</sup>: RelB-deficient; wt: wild-type; mAb: monoclonal antibody; EMSA: electrophoretic mobility shift assay; FC: fold change; MDFC: minimal detectable fold change; cat: category; JNK: c-Jun N-terminal kinase; LIGHT: lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells; FDC: follicular dendritic cell; GC: germinal center; HEV: high endothelial venule; A/CD: apoptosis/cell death; CCY: cell cycle; IR: immune related; BR: blood vessel development related; T: taxis, response to external/chemical stimulus; ION: ion homeostasis; LY: hematopoietic or lymphoid organ developmental processes; qRT-PCR: quantitative real-time reverse-transcription PCR; IL-1: interleukin-1; MSR: Manufactory Slide Report; SD: standard deviation.</p></sec><sec><title>Authors' contributions</title><p>AL: carried out the molecular genetic studies, analyzed and interpreted data, drafted manuscript. DR: carried out the bioinformatic and statistic analysis, participated in study design, analyzed and interpreted data. DA: participated in the bioinformatic and statistic analysis, analyzed and interpreted data. ZBY: initiated and participated in the molecular genetic studies. UM: participated in the bioinformatic and statistic analysis. AJRH: supported bioinformatic analysis. FW: conceived the study, participated in its design and coordination, interpreted data, helped to write the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Total LT&#x003b2;R transcriptome in wt cells</bold>. List of the 528 genes that were LT&#x003b2;R responsive in wt cells (10 h), regardless whether they were also regulated in <italic>relA</italic><sup>-/- </sup>or <italic>relB</italic><sup>-/- </sup>cells, or not.</p></caption><media xlink:href="1471-2164-9-606-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>LT&#x003b2;R-responsive genes in wt cells</bold>. List of genes that were significantly regulated in wt cells, but not in <italic>relA</italic><sup>-/- </sup>or <italic>relB</italic><sup>-/- </sup>cells (10 h; upregulation, cat I/1, n = 161; downregulation, cat I/2, n = 205).</p></caption><media xlink:href="1471-2164-9-606-S2.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>LT&#x003b2;R-responsive genes in wt and <italic>relA</italic><sup>-/- </sup>cells</bold>. List of genes that were significantly regulated in wt and in <italic>relA</italic><sup>-/- </sup>cells (10 h; upregulation, cat II/1, n = 13; downregulation, cat II/2, n = 17).</p></caption><media xlink:href="1471-2164-9-606-S3.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>LT&#x003b2;R-responsive genes in wt and <italic>relB</italic><sup>-/- </sup>cells</bold>. List of genes that were significantly regulated in wt and in <italic>relB</italic><sup>-/- </sup>cells (10 h; upregulation, cat III/1, n = 54; downregulation, cat III/2, n = 43; cat III/3, n = 3; cat III/4, n = 2).</p></caption><media xlink:href="1471-2164-9-606-S4.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p><bold>LT&#x003b2;R-responsive genes in wt, <italic>relA</italic><sup>-/- </sup>and <italic>relB</italic><sup>-/- </sup>cells</bold>. List of genes that were significantly regulated in each of the genotypes (10 h; upregulation, cat IV/1, n = 20; downregulation, cat IV/2, n = 10).</p></caption><media xlink:href="1471-2164-9-606-S5.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title>Additional file 6</title><p><bold>Zoomable/enlarged version of fold change heatmaps</bold>. Heatmaps displaying the fold change values observed in the three different cell lines at 10 h compared to 0 h. For figure legend see Figure <xref ref-type="fig" rid="F3">3</xref>. Gene symbols and GenBank Accession Numbers (in brackets) are also displayed.</p></caption><media xlink:href="1471-2164-9-606-S6.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Jeffrey Browning and Paul Rennert for agonistic anti-LT&#x003b2;R mAb and Alexander Hoffmann for mouse embryonic 3T3 fibroblasts (wild-type, <italic>relA</italic><sup>-/-</sup>, and <italic>relB</italic><sup>-/-</sup>). We gratefully acknowledge Heike Mondrzak, Ulrike Schure, Melissa Lehmann, Kerstin Andreas, and Sandra Westhaus for technical help with the qRT-PCR. We are indebted to Hans Peter Saluz for providing us with the possibility to use the GenePix 4000B Array Scanner. We also thank Marc Riemann for valuable discussions on this manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Missing pieces in the NF-kappaB puzzle</article-title><source>Cell</source><year>2002</year><volume>109</volume><fpage>S81</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11983155</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00703-1</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Signaling to NF-kappaB</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>2195</fpage><lpage>2224</lpage><pub-id pub-id-type="pmid">15371334</pub-id><pub-id pub-id-type="doi">10.1101/gad.1228704</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Shared principles in NF-kappaB signaling</article-title><source>Cell</source><year>2008</year><volume>132</volume><fpage>344</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">18267068</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2008.01.020</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>A</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name></person-group><article-title>Transcriptional regulation via the NF-kappaB signaling module</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>6706</fpage><lpage>6716</lpage><pub-id pub-id-type="pmid">17072323</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209933</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dejardin</surname><given-names>E</given-names></name><name><surname>Droin</surname><given-names>NM</given-names></name><name><surname>Delhase</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>E</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Makris</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>ZW</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><article-title>The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways</article-title><source>Immunity</source><year>2002</year><volume>17</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">12387745</pub-id><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00423-5</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derudder</surname><given-names>E</given-names></name><name><surname>Dejardin</surname><given-names>E</given-names></name><name><surname>Pritchard</surname><given-names>LL</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Korner</surname><given-names>M</given-names></name><name><surname>Baud</surname><given-names>V</given-names></name></person-group><article-title>RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>23278</fpage><lpage>23284</lpage><pub-id pub-id-type="pmid">12709443</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M300106200</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>JR</given-names></name><name><surname>Siebenlist</surname><given-names>U</given-names></name></person-group><article-title>Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>12006</fpage><lpage>12012</lpage><pub-id pub-id-type="pmid">12556537</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M210768200</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Caamano</surname><given-names>J</given-names></name></person-group><article-title>Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway</article-title><source>Immunol Rev</source><year>2003</year><volume>195</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">12969313</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-065X.2003.00064.x</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>ZB</given-names></name><name><surname>Weih</surname><given-names>DS</given-names></name><name><surname>Sivakumar</surname><given-names>V</given-names></name><name><surname>Weih</surname><given-names>F</given-names></name></person-group><article-title>RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">12505990</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdg004</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonizzi</surname><given-names>G</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>The two NF-kappaB activation pathways and their role in innate and adaptive immunity</article-title><source>Trends Immunol</source><year>2004</year><volume>25</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">15145317</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2004.03.008</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dejardin</surname><given-names>E</given-names></name></person-group><article-title>The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development</article-title><source>Biochem Pharmacol</source><year>2006</year><volume>72</volume><fpage>1161</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">16970925</pub-id><pub-id pub-id-type="doi">10.1016/j.bcp.2006.08.007</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basak</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kearns</surname><given-names>JD</given-names></name><name><surname>Tergaonkar</surname><given-names>V</given-names></name><name><surname>O'Dea</surname><given-names>E</given-names></name><name><surname>Werner</surname><given-names>SL</given-names></name><name><surname>Benedict</surname><given-names>CA</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name></person-group><article-title>A fourth IkappaB protein within the NF-kappaB signaling module</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">17254973</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.12.033</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basak</surname><given-names>S</given-names></name><name><surname>Shih</surname><given-names>VF</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name></person-group><article-title>Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system</article-title><source>Mol Cell Biol</source><year>2008</year><volume>28</volume><fpage>3139</fpage><lpage>3150</lpage><pub-id pub-id-type="pmid">18299388</pub-id><pub-id pub-id-type="doi">10.1128/MCB.01469-07</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basak</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name></person-group><article-title>Crosstalk via the NF-kappaB signaling system</article-title><source>Cytokine Growth Factor Rev</source><year>2008</year><volume>19</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">18515173</pub-id><pub-id pub-id-type="doi">10.1016/j.cytogfr.2008.04.005</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mebius</surname><given-names>RE</given-names></name></person-group><article-title>Organogenesis of lymphoid tissues</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12669020</pub-id><pub-id pub-id-type="doi">10.1038/nri1054</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>K</given-names></name><name><surname>Potter</surname><given-names>KG</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name></person-group><article-title>Lymphotoxin and LIGHT signaling pathways and target genes</article-title><source>Immunol Rev</source><year>2004</year><volume>202</volume><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15546385</pub-id><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00206.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>CF</given-names></name></person-group><article-title>Network communications: lymphotoxins, LIGHT, and TNF</article-title><source>Annu Rev Immunol</source><year>2005</year><volume>23</volume><fpage>787</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">15771586</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115719</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">7603567</pub-id><pub-id pub-id-type="doi">10.1038/376167a0</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Durham</surname><given-names>SK</given-names></name><name><surname>Barton</surname><given-names>DS</given-names></name><name><surname>Rizzo</surname><given-names>CA</given-names></name><name><surname>Ryseck</surname><given-names>RP</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group><article-title>Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">7834753</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(95)90416-6</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weih</surname><given-names>DS</given-names></name><name><surname>Yilmaz</surname><given-names>ZB</given-names></name><name><surname>Weih</surname><given-names>F</given-names></name></person-group><article-title>Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>1909</fpage><lpage>1919</lpage><pub-id pub-id-type="pmid">11489970</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Subudhi</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><article-title>Contribution of the lymphotoxin beta receptor to liver regeneration</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>1295</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">16002734</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tumanov</surname><given-names>AV</given-names></name><name><surname>Bamji</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Reardon</surname><given-names>CA</given-names></name><name><surname>Getz</surname><given-names>GS</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group><article-title>Lymphotoxin beta receptor-dependent control of lipid homeostasis</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">17431181</pub-id><pub-id pub-id-type="doi">10.1126/science.1137221</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Hsieh</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name></person-group><article-title>Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation</article-title><source>Exp Cell Res</source><year>2002</year><volume>278</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12169272</pub-id><pub-id pub-id-type="doi">10.1006/excr.2002.5573</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name><name><surname>Liu</surname><given-names>ZG</given-names></name></person-group><article-title>TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>2130</fpage><lpage>2137</lpage><pub-id pub-id-type="pmid">15743811</pub-id><pub-id pub-id-type="doi">10.1128/MCB.25.6.2130-2137.2005</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saccani</surname><given-names>S</given-names></name><name><surname>Pantano</surname><given-names>S</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name></person-group><article-title>Modulation of NF-kappaB activity by exchange of dimers</article-title><source>Mol Cell</source><year>2003</year><volume>11</volume><fpage>1563</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">12820969</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00227-2</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bren</surname><given-names>GD</given-names></name><name><surname>Solan</surname><given-names>NJ</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Pennington</surname><given-names>KN</given-names></name><name><surname>Pobst</surname><given-names>LJ</given-names></name><name><surname>Paya</surname><given-names>CV</given-names></name></person-group><article-title>Transcription of the RelB gene is regulated by NF-kappaB</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>7722</fpage><lpage>7733</lpage><pub-id pub-id-type="pmid">11753650</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1204868</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Thielen</surname><given-names>C</given-names></name><name><surname>Seeger</surname><given-names>H</given-names></name><name><surname>Schwarz</surname><given-names>P</given-names></name><name><surname>Montrasio</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Heinen</surname><given-names>E</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name><name><surname>Miele</surname><given-names>G</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Lymphotoxin-beta receptor-dependent genes in lymph node and follicular dendritic cell transcriptomes</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>5526</fpage><lpage>5536</lpage><pub-id pub-id-type="pmid">15843551</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>JL</given-names></name><name><surname>French</surname><given-names>LE</given-names></name></person-group><article-title>Visualization of lymphotoxin-beta and lymphotoxin-beta receptor expression in mouse embryos</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>5079</fpage><lpage>5087</lpage><pub-id pub-id-type="pmid">11994460</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Newton</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Gunn</surname><given-names>MD</given-names></name><name><surname>Rosen</surname><given-names>SD</given-names></name></person-group><article-title>Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">18327261</pub-id><pub-id pub-id-type="doi">10.1038/ni1573</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>JL</given-names></name><name><surname>Allaire</surname><given-names>N</given-names></name><name><surname>Ngam-Ek</surname><given-names>A</given-names></name><name><surname>Notidis</surname><given-names>E</given-names></name><name><surname>Hunt</surname><given-names>J</given-names></name><name><surname>Perrin</surname><given-names>S</given-names></name><name><surname>Fava</surname><given-names>RA</given-names></name></person-group><article-title>Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">16286021</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2005.10.002</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonizzi</surname><given-names>G</given-names></name><name><surname>Bebien</surname><given-names>M</given-names></name><name><surname>Otero</surname><given-names>DC</given-names></name><name><surname>Johnson-Vroom</surname><given-names>KE</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Vu</surname><given-names>D</given-names></name><name><surname>Jegga</surname><given-names>AG</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name><name><surname>Rickert</surname><given-names>RC</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>4202</fpage><lpage>4210</lpage><pub-id pub-id-type="pmid">15470505</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600391</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>GE</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>RD</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name><name><surname>Bacon</surname><given-names>KB</given-names></name><name><surname>Zerwes</surname><given-names>HG</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name></person-group><article-title>NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS</article-title><source>J Leukoc Biol</source><year>2000</year><volume>67</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">10770292</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barlic</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFalpha-NFkappaB-dependent manner</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>19167</fpage><lpage>19176</lpage><pub-id pub-id-type="pmid">17456471</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M701642200</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lukashev</surname><given-names>M</given-names></name><name><surname>LePage</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Bailly</surname><given-names>V</given-names></name><name><surname>Garber</surname><given-names>E</given-names></name><name><surname>Lukashin</surname><given-names>A</given-names></name><name><surname>Ngam-ek</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Allaire</surname><given-names>N</given-names></name><name><surname>Perrin</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Szeliga</surname><given-names>K</given-names></name><name><surname>Wortham</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>R</given-names></name><name><surname>Bottiglio</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>L</given-names></name><name><surname>Heaney</surname><given-names>G</given-names></name><name><surname>Silverio</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Jarpe</surname><given-names>M</given-names></name><name><surname>Fawell</surname><given-names>S</given-names></name><name><surname>Reff</surname><given-names>M</given-names></name><name><surname>Carmillo</surname><given-names>A</given-names></name><name><surname>Miatkowski</surname><given-names>K</given-names></name><name><surname>Amatucci</surname><given-names>J</given-names></name><name><surname>Crowell</surname><given-names>T</given-names></name><name><surname>Prentice</surname><given-names>H</given-names></name><name><surname>Meier</surname><given-names>W</given-names></name><name><surname>Violette</surname><given-names>SM</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Browning</surname><given-names>JL</given-names></name></person-group><article-title>Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>9617</fpage><lpage>9624</lpage><pub-id pub-id-type="pmid">17018619</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0217</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Miki</surname><given-names>H</given-names></name><name><surname>Tamemoto</surname><given-names>H</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Komeda</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>R</given-names></name><name><surname>Ishii</surname><given-names>C</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Eto</surname><given-names>K</given-names></name><name><surname>Tsubamoto</surname><given-names>Y</given-names></name><name><surname>Okuno</surname><given-names>A</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Sekihara</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>G</given-names></name><name><surname>Naito</surname><given-names>M</given-names></name><name><surname>Toyoshima</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Shiota</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Ezaki</surname><given-names>O</given-names></name><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance</article-title><source>Mol Cell</source><year>1999</year><volume>4</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">10549291</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80210-5</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzawa</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>I</given-names></name><name><surname>Yanagisawa</surname><given-names>J</given-names></name><name><surname>Ohtake</surname><given-names>F</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Shibuya</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name></person-group><article-title>Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade</article-title><source>Nat Cell Biol</source><year>2003</year><volume>5</volume><fpage>224</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">12598905</pub-id><pub-id pub-id-type="doi">10.1038/ncb942</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group><article-title>Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen</article-title><source>Oncogene</source><year>1994</year><volume>9</volume><fpage>3289</fpage><lpage>3297</lpage><pub-id pub-id-type="pmid">7936653</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>E</given-names></name><name><surname>Matthias</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>MM</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name></person-group><article-title>Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells</article-title><source>Nucleic Acids Res</source><year>1989</year><volume>17</volume><fpage>6419</fpage><pub-id pub-id-type="pmid">2771659</pub-id><pub-id pub-id-type="doi">10.1093/nar/17.15.6419</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>J R Stat Soc Ser B</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozen</surname><given-names>S</given-names></name><name><surname>Skaletsky</surname><given-names>H</given-names></name></person-group><article-title>Primer3 on the WWW for general users and for biologist programmers</article-title><source>Methods Mol Biol</source><year>2000</year><volume>132</volume><fpage>365</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">10547847</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutsch</surname><given-names>S</given-names></name><name><surname>Degrandi</surname><given-names>D</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name></person-group><article-title>Immediate lymphotoxin beta receptor-mediated transcriptional response in host defense against L. monocytogenes</article-title><source>Immunobiology</source><year>2008</year><volume>213</volume><fpage>353</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">18406380</pub-id><pub-id pub-id-type="doi">10.1016/j.imbio.2007.10.011</pub-id></citation></ref></ref-list></back></article> 